WO2005120616A1 - Securing dose quality of inhalable drug - Google Patents

Securing dose quality of inhalable drug Download PDF

Info

Publication number
WO2005120616A1
WO2005120616A1 PCT/SE2005/000843 SE2005000843W WO2005120616A1 WO 2005120616 A1 WO2005120616 A1 WO 2005120616A1 SE 2005000843 W SE2005000843 W SE 2005000843W WO 2005120616 A1 WO2005120616 A1 WO 2005120616A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhaler
dose
slide
position
container
Prior art date
Application number
PCT/SE2005/000843
Other languages
French (fr)
Inventor
Mattias Myrman
Original Assignee
Mederio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SE0401453A priority Critical patent/SE528190C2/en
Priority to SE0401453-6 priority
Priority to SE0401612-7 priority
Priority to SE0401612A priority patent/SE530006C2/en
Application filed by Mederio Ag filed Critical Mederio Ag
Publication of WO2005120616A1 publication Critical patent/WO2005120616A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Abstract

A method and a device for making a metered dry powder medication dose, enclosed in a dose container, accessible for inhalation with a minimum of exposure to ambient atmosphere. The invention relates to a single dose inhaler, which is provided with a movable inhaler member, a so called slide, which has at least one matching receptacle adapted for receiving a selected type of dose container. The slide is movable between a first, protuding position, where the receptacle(s) is accessible for loading of a sealed dose container by a user, and a second, retracted position inside the inhaler.

Description

Securing dose quality of inhalable drug TECHNICAL FIELD

The present invention relates to a method and a device applied in a single dose dry powder inhaler for bringing a medicament dose into the dry powder inhaler in preparation of an inhalation of the dose being enclosed in a sealed dose container.

BACKGROUND

Within health care today administration of medicaments by inhalation for distributing dry powder medicaments directly to the airways and lungs of a user is becoming more and more popular, because it offers an efficient, fast, and user friendly delivery of the specific medication substance.

Different types of inhalers are available on the market today, such as metered dose inhalers (MDIs), nebulizers and dry powder inhalers (DPIs). MDIs use medicaments in liquid form and may use a pressurized drive gas to release a dose. Usually MDIs have a relatively low capacity for delivering an effective dose of the active substance in a single inhalation and many devices have problems with using a drive gas, which is environmentally acceptable. Nebulizers are fairly big, non-portable devices. Dry powder inhalers have become more and more accepted in the medical service, because they deliver an effective dose in a single inhalation, they are reliable, often quite small in size and easy to operate for a user. Two types are common, multi-dose dry powder inhalers and single dose dry powder inhalers. Multi-dose devices have the advantage that a quantity of medicament powder, enough for a large number of doses, is stored inside the inhaler and a dose is metered from the store shortly before it is supposed to be inhaled. Single dose inhalers either require reloading after each administration or they may be loaded with a limited number of individually packaged doses, where each package is opened shortly before inhalation of the enclosed dose is supposed to take place. Gelatin or plastic capsules and blisters made of aluminum or plastic, or laminates comprising aluminum and plastic foil are common prior art containers for metered single doses of dry powder medicaments. Typically, the user has to open the inhaler, insert at least one container into the inhaler, close it, push a button to force one or more sharp instrument(s) to penetrate a selected container, such that the dose may be accessed by streaming air when the user at leisure decides to inhale the dose. Besides a method of breaking the container open inside the inhaler and pour out the dose in a chamber first, the most common method of opening the container is to punch one or more holes in the container itself or in a foil sealing the container. In the first case the powder is poured onto a surface inside the inhaler and made available for inhalation from there. In the second case the dose is aerosolized by inhalation air being forced through the container or the dose being shaken out of the container and immediately aerosolized' by streaming air on the outside of the container.

There is a demand for an improved method and device, which will simplify loading and opening of the dose container to make the powder dose enclosed therein easily available to a user of the DPI.

SUMMARY

A method of making a metered dry powder medication dose, enclosed in a dose container, accessible for inhalation with a minimum of exposure to ambient atmosphere and a hand-operated device for carrying out the method are disclosed.

The present invention relates to a single dose inhaler, which is provided with a movable inhaler member, a so called slide, which has at least one matching receptacle adapted for receiving a selected type of dose container. The slide is movable between a first, protuding position, where the receptacle(s) is accessible for loading of a sealed dose container by a user, and a second, retracted position inside the inhaler. In a particular embodiment the slide carrying an unopened, sealed dose container is arranged to be pushed by a user's hand force from the first position to the second position. During the motion the seal of the dose container is opened by an opening member provided inside the inhaler. As the container continues into the inhaler by the pushing action the dose inside the container is accessed by an inhalation-induced flow element, e.g. directed by a suction nozzle being in close proximity to the dose as it, too, moves into the inhaler carried by the slide.

Optionally, the inhaler is provided with a breath-actuated latch mechanism preventing the slide from being pushed from the first position, if the receptacle is loaded with a dose container, unless a suction exceeding a certain minimum magnitude is provided by the user sucking at a mouthpiece of the inhaler. This breath-actuation helps the user to synchronize the pushing action with an act of inhalation.

DESCRIPTION OF THE DRAWINGS

The invention will be described in the form of a preferred and illustrative embodiment and by means of the attached drawings, wherein like reference numbers indicate like or corresponding elements and wherein:

FIG. 1 illustrates in a flow diagram a particular method of the present invention;

FIG. 2 illustrates a slide applied in a single dose dry powder inhaler in a top view with slide in a protruding position (Fig. 2a) and slide in a retracted position (Fig. 2b) and a side view (Fig. 2c) of slide and inhaler;

FIG. 3 illustrates a sealed dose container carrying an enclosed dose adapted for the slide in Fig. 2; FIG. 4 illustrates in perspective (Fig. 4a), top (Fig. 4b) and front (Fig. 4c) views a particular embodiment of a sealed dose container, adapted for the present invention.

FIG. 5 illustrates two typical inhalation sequences (Fig 5a and Fig. 5b) when applying the present invention to a dry powder inhaler.

DESCRIPTION OF AN ILLUSTRATIVE EMBODIMENT

The present invention relates to a method and a device for making a metered dry powder medication dose in a dose container accessible inside a dry powder inhaler (DPI) in direct connection with an inhalation of the enclosed dose.

Advantages brought by the disclosure are Secures dose quality Simple inhaler design Few parts needed Low cost Small inhaler size Ease, of use Safety High level of user compliance Titratable dosing by user possible, i.e. different dose sizes may be selected by user • All types of inhalable dry powder drugs may be used

In a particular aspect of the present invention, the method comprises bringing a sealed container carrying a single medicament dose into the inhaler by means of a movable inhaler member, a so called slide. A user has access to the slide in a first, protruding position. The slide comprises at least one matching receptacle designed for a particular type of dose container. An advantage of the invention is that the user has access to the slide, but no access to the internal parts of the inhaler, whereby unintentional damage or contamination of sensitive parts is avoided. Pushing the slide inwards into the inhaler body, the motion ends in a second, retracted position. Pushing the slide is done preferably by hand or optionally by a motor. The dose container is thus brought into the inhaler. The user pushes the slide into the inhaler while at the same time inhaling through a mouthpiece of the inhaler. As the dose container enters the inhaler, the container seal begins to be opened up by an opener device integrated in the inhaler, thereby letting ambient air into the container and into the dose powder. But at the same time one or more flow elements of the inhaler gains access to the dose and a concurrent release of the dose into an inhalation air-stream begins. The time lapse between opening of the seal and dose release is extremely short, which secures the quality of the dose when delivered to the inhaling user. Typically, the time the particles of the dose are exposed to the atmosphere before they are entrained into inspiration air is only a split second. When the slide reaches a second, fully retracted position, the dose has already been delivered. Preferably, however, the slide cannot move from the first position unless a sufficiently strong inhalation is already in progress. Thus, the transport, container opening and dose delivery are carried out in a single user-initiated action. In this way, the dose is exposed to the atmosphere for a minimum time, in fact only for the duration of a complete dose delivery. The exposure of the dose to the atmosphere is consistently short every time and actually less than the inhalation time itself.

In a further aspect of the invention, illustrated in Figure 2a, 2b and 2c, the slide 15 is provided with at least one matching receptacle 16 for a selected type of single dose container 33 in a protective casing 41. Only the defined selected type of dose container 33+41 can be inserted into the receptacle. After the dose has been delivered the slide remains in the second, retracted position until the user activates the slide, such that it comes out of the inhaler 12 carrying the now spent empty container. The user removes the spent container 33+41 and discards it. Pushing the slide without container back into the inhaler closes the inhaler shut. The user may activate the slide as needed when the time comes for administering a new dose. Thus, the user needs never to have access to the inside of the inhaler. According to the present invention, this novel method of protecting a dose and bringing it into an inhaler 12, having a mouthpiece 11, makes it possible to arrange a very efficient, high quality dose delivery with negligible risk of dose degradation and of foreign matter being accidentally introduced into the inhaler by the user.

By relying on the user to provide the energy to move the slide and the inhalation effort for delivering the dose, a very simple, compact and robust inhaler design is possible. As a result the cost is low and the uncomplicated design makes the manufacturing simple and very little can go wrong with the inhaler in the hands of a user.

A particular method is described in a flow chart illustrated in Figure 1. A movable inhaler member, constituting a slide, being in a normal, fully retracted position inside the inhaler body, is activated in an optional step 100 by e.g. a pushbutton accessible on the inhaler. Preferably, the slide is held in the fully retracted position by a latch mechanism, so that it cannot move until the latch is released by any suitable means, e.g. a spring loaded pushbutton. Preferably, when the slide is released it will come out of the inhaler automatically, i.e. without further assistance from a user, into a first, fully protruding, dose loading position, step 110, where the slide is ready to accept at least one dose container. If the inhaler has been used before, it is possible that a spent container is still held in at least one receptacle in the slide and must be removed before a new one can be fitted. A new, selected container of the correct type may now be snapped into the matching receptacle, step 120. Preferably, the container snaps into place and remains firmly held there, with no possibility of moving relative the slide. In a particular embodiment of the present invention, on condition that a user has started an inhalation, step 130, the slide is now pushed inwards into the inhaler, step 140, bringing the container with it. As the container enters the inhaler body it is opened, step 150, by suitable opening means and a stream of air is then directed to the dose by an adapted flow element, e.g. a suction nozzle, step 160. The particles of the dose are thereby released and entrained into the inspiration airflow leaving the mouthpiece , step 170. In a preferred embodiment of the present invention, the container is opened while being transported into the inhaler. In an alternative embodiment the container may be opened when the slide reaches its second, fully retracted position, or proximate this position, inside the inhaler. See Figure 5 which illustrates a typical opening of a container synchronized with an inhalation. Diagram curve Y represents the suction power in kPa provided by the user over time X and curve Z represents the container motion from 0 (starting position) to 100 % (end position) in the DPI.

In a preferred embodiment according to the disclosure, however, it is advantageous that the bringing of the slide with a dose container into the inhaler is synchronized to a commenced inhalation, such that the time during which the dose is exposed to the ambient atmosphere is minimized. Obviously, the container must be opened before a stream of air can access the dose. Preferably, the container starts to be opened at a predetermined point along the stroke made by the slide. A stream of inspiration air is directed into the container as it is being opened, whereby the air-stream gains access to the enclosed dose.

The disclosed method must be adapted to the particular type of dose container, which has been selected for insertion into a particular, adapted dry powder inhaler. For instance, the receptacle in the slide, firmly holding the dose container, must be adapted and matched to the container type. Naturally, the piercing or opening members and the flow elements inside the inhaler must also be adapted for the container type. Thus, the air flow resulting from an inhalation is directed by proper channeling into the dose container, preferably as soon as the container is being opened by the piercing or opening members of the inhaler, such that the stream of air may release the dose and bring the dose into the inspiration air of a user without unnecessary delay. As already pointed out, different types of dose containers may be selected and advantageously used in the present invention. Examples of containers are aluminum or plastic single dose blisters of varying size and design and also capsules of gelatin, cellulose or plastics. A person of ordinary skill in the art will know how to adapt the receptacle in the slide, the insertion of the dose container into the inhaler and the inhaler itself, including the piercing or cutting members and air flow channels, to a particular type of dose container.

The disclosed method eliminates as far as possible any adverse influence that e.g. humidity in the air may have on the fine particles in the dose, such as creating particle aggregates and making aggregates more difficult to de- aggregate when sucked up and delivered to a user of the inhaler. Minimizing the dose exposure to the atmosphere may preferably be done by implementing a breath actuation mechanism in the inhaler. The breath actuation blocks the bringing of the slide and container into the inhaler until the user applies at least a minimum suction power to a mouthpiece of the inhaler. For instance, a pressure sensitive flap may be arranged to open when the applied suction is strong enough, thus letting air flow into the air channels of the inhaler, which are in fluid connection with the mouthpiece. When the flap opens, the blocking of the slide is removed and the slide, may be pushed into the inhaler while the inhalation is in an early stage of progress.

In a further aspect of the present invention a damper mechanism is attached to the slide. In a particular embodiment the damper device provides a first counterforce counteracting the slide motion out of the inhaler body after the slide has been activated and released from its fully retracted position. The slide motion out of the inhaler may optionally but preferably be governed and powered by a spring mechanism that provides a spring force, which is reasonably constant. The spring-driven motion is balanced by the damper device along the full stroke, or part thereof, of the slide from a second, fully retracted position into a first, fully protruding position. The speed of the slide coming out of the inhaler is thus kept constant. The same or a different damper may provide a second counterforce, which may or may not be of the same magnitude as the first counterforce, opposing an applied force pushing the slide back into the inhaler body. The applied pushing force may be a manual force provided by a user of the inhaler, or it may be provided by an independent source of power, e.g. in a particular embodiment where the slide is governed and powered by an electric motor device. The damper acts to control the speed of the slide motion into the inhaler by providing a suitable, second counterforce formed by the damper, such that the speed of the slide into the inhaler is kept reasonably constant.

Disregarding the cost aspect, a motorized drive system may replace the spring mechanism and optionally the dampers and/ or the manual pushing force provided by a user. This version of moving the slide may e.g. be used where a user has physical handicaps, which restricts or excludes manual use of the device. As a person skilled in the art will realize, the driving force, necessary for driving the relative motion of the slide in and out of the inhaler, may come from any type of power source, e.g. electric, hydraulic, pneumatic, spring, mechanical or manual by a user. However, hand operation by a user is normally preferred, because it offers a low cost, simple and safe administration of any type of inhalable dry powder drug.

In another embodiment, however, when a dose container is selected, which is not suitable for concurrent transport, opening and dose delivery, the disclosed method and device may be adjusted to comprise the bringing of the container into a position in the inhaler where the container may be kept in an unopened state prepared for later delivery. Preferably, a movable inhaler member, e.g. a slide, is used for bringing the container into this position and keeping it there, until the container is opened by suitable means incorporated in the inhaler, e.g. an opener or one or more sharp, piercing instrument. Preferably, opening is triggered by an act of inhalation, such that the enclosed dose may be entrained into inspiration air directly from the container as soon as the container has been opened. In this case too, the user has no access to the internals of the inhaler. However, such alternative embodiments might prevent that a gradual and optionally prolonged release of the dose is obtained. This is an important feature obtained in the preferred embodiment. A corresponding function of another embodiment, where the slide with the dose container is resting inside the device before commencing an inhalation, will make this embodiment more complicated leading to a more expensive design of the particular adapted inhaler.

In another aspect of the present invention, the time between opening of a selected dose container and inhalation of the enclosed dose is on the order of a split second, which is so short that it is negligible. Prior art inhalers allow much longer times between subjecting the selected dose to the ambient atmosphere and an actual inhalation of the dose taking place. Some prior art inhalers have no control over time lapse between breaking the dose container open and a following inhalation. In any case, by the influence of the ambient atmosphere and especially moisture, the dose may decompose rapidly, such that when the user finally gets round to inhaling the dose, it may have deteriorated seriously. The user will then unknowingly get a smaller therapeutic effect than intended.

Generally, dry powder medicament doses need to be protected by an enclosure not only during storage, but also when inserted in an inhaler where the dose and its enclosure are kept in a ready state for delivery in an inhalation at a point in time decided by the user. New types of dry powder medicaments, not least for systemic treatment, have a rather short expiry date and they are generally quite sensitive to ambient conditions, especially moisture during storage and in use. Hence, the demands put on dose protection and inhaler devices in handling sensitive doses are therefore much higher than for prior art devices as used e.g. for administering traditional medicaments against respiratory disorders. For instance, prior art blister packages for dry powder medicaments, intended for inhaler use, often use a fairly thin polymeric seal, which can be easily ripped or punched open before the dose is supposed to be inhaled. Another common seal is a peelable blister such that the blister is peeled open prior to inhalation of the enclosed dose. Yet another type of prior art dose container is the capsule. Capsules are often made by gelatin, but polymers and cellulose and other materials are also used. A common problem for prior art blisters and capsules used for dry powder doses for inhalation is that the primary package does not protect sensitive substances from moisture well enough during storage and in use. Minimizing the time the primary package is exposed to the atmosphere and minimizing the time during which the dose is subjected to the ambient atmosphere after opening of the container' are therefore important aspects of inhaler and dose container design.

Naturally, using a new type of blister pack, a so-called pod, as a particular embodiment of a sealed dose container, is to be preferred in an application where the present invention is to be put to use. See Figure 3 illustrating a sealed dose container 33 in a protective casing 41. The container encloses a dose 23, illustrated for the benefit of the reader, although the dose is located under a seal 31. Containers providing high quality high barrier seals, such as a pod, are particularly suited for use of the present invention. High barrier seals require a pushing force of considerable strength to power opening of the seal. The hand operated slide provides ample power to overcome resistance from the sealing, as opposed to many prior art inhalers. See Figure 4 illustrating a pod carrying a sealed container in a perspective drawing. Figure 4a shows a sealed container 33 (seal 31) put into a protective casing 41 adapted for insertion into a dry powder inhaler. Figure 4b shows a top view of the carrier/ container and indicates depositions of dry- powder making up a metered dose inside the container 33 under a seal 31, for the benefit of the reader. Figure 4c illustrates a front view of the carrier/ container in Figure 4b.

However, the present invention may also advantageously be applied to conventional blister packs and capsules. Preferably, a person skilled in the art may use the disclosure by adapting e.g. when the container seal is to be opened during the course of moving the container from a starting position to an end position and adapting how it is opened to the particular type of container that is selected for use. Such adaptation is still within the scope of the present invention. An objective of the present invention is to make the time between opening of the container and delivery of the dose inside as short as possible and to make it impossible for the user to open the container without commencing an inhalation. If an inhalation is broken off prematurely for any reason, then the user will at least be aware that a full dosage may not have been delivered.

In cases where the medicament dosage is controlled by the user, a single dose dry powder inhaler is preferred, because the user may then select a dosage among pre-metered doses, which is well adjusted to the situation and condition the user is in.

It will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departing from the scope thereof, which is defined by the appended claims.

Claims

1. A method of reducing time of exposure of a medical dry powder dose enclosed in a sealed dose container to ambient atmosphere in connection with an inhalation of said dose using a single dose dry powder inhaler, characterized by the steps of snapping the dose container into a matching receptacle of a movable inhaler member, a slide, being in a first, protruding position; synchronizing an act of inhalation and a pushing of the slide back into the inhaler from the first position of slide into a second, retracted position; bringing the dose container gradually inside the inhaler by the slide motion where the dose container seal is opened up during the motion and one or more inhaler flow elements are concurrently accessing and releasing the dose before the slide has reached the second position, whereby the time lapse between opening of seal and dose release, i.e. exposure to ambient atmosphere, is extremely short.
2. The method according to claim 1, characterised by the further step of releasable locking the dose container in its matching receptacle, such that it cannot move relative the slide;
3. The method according to claim 1, characterised by the further step of securing quality of the enclosed metered medication dose by minimizing its exposure time to ambient atmosphere.
4. The method according to claim 1, characterised by the further step of limiting the time lapse, i.e. the time for moving the slide from the first into the second position, to less than 5 s and preferably less than 2 s.
5. The method according to claim 1, characterised by the further step of activating the slide when in the second, retracted position inside the inhaler body, whereby the slide is released and permitted to extend out of the inhaler body into the first, protruding position, the motion out of the inhaler optionally not requiring assistance by a user.
6. The method according to claim 1, characterised by the further step of latching the motion from the first position of the slide into the inhaler to a breath-actuation mechanism of the inhaler, which requires suction to be applied to a mouthpiece of the inhaler whereby a certain minimum suction pressure has to be exceeded before the motion of the movable inhaler member can begin.
7. The method according to claim 1, characterised by the further step of resisting motion of the slide from the first position to the second position by applying a controlled counterforce balancing the pushing force, such that the speed of the motion is kept generally constant from the first to the second position.
8. The method according to claim 1, characterised by the further step of using a spring to power the motion of the slide out of the inhaler body from the second position into the first position.
9. The method according to claim 1, characterised by the further step of adjusting the speed of the movable member, such that the time for pushing the movable member from the first position to the second position is not less than 0.2 s and not more than 2 s.
10. The method according to claim 1, characterised by the further step of opening the dose container when the movable member is in the retracted position or in close proximity to the retracted position.
11. A slide device for bringing a dose container harbouring an enclosed, metered, dry powder medication dose into a single dose dry powder inhaler for securing quality of the medication dose characterized in that the slide device constitutes a user-activated member of the inhaler, reversibly movable between a first, protruding position and a second, retracted position in the inhaler, the slide device comprising: at least one matching receptacle for a dose container of a selected type; a braking means limiting the speed of the slide motion from the first to the second position;
12. The slide device according to claim 11, characterised in that the slide device comprises a latch for preventing the motion of the slide device from the first position into the inhaler, the latch connecte to a breath-actuation mechanism of the inhaler, the breath-actuation mechanism requiring a certain minimum suction pressure to be exceeded by a user applying a suction to a mouthpiece of the inhaler, before releasing the latch such that motion of the slide device can begin.
13. The slide device according to claim 11, characterised in that a driving spring is arranged for driving the slide from the second, retracted position out of the inhaler body into a first, protruding position, the spring optionally combined with a braking means to limit the speed of motion.
14. The slide device according to claim 13, characterised in that a damper unit is used as braking means, presenting a controlled counterforce balancing a pushing force by the driving spring, such that the speed of the motion is generally constant.
15. The slide device according to claim 11, characterised in that a motor is used to power the motion of the slide device out of and into the inhaler body, replacing the driving spring and the pushing by a user.
16. A method of bringing a dose container, holding an enclosed, metered, dry powder medication dose, into a single dose dry powder inhaler in preparation for an inhalation sequence, characterized by the steps of activating a movable inhaler member in a second, retracted position inside the inhaler body, whereby the movable member is released to move out of the inhaler body into a first, protruding position, the motion of the movable member optionally not requiring assistance by a user; snapping the dose container into a matching receptacle of the movable member, the container optionally becoming locked in its receptacle, such that it cannot move relative the movable member; pushing the movable member back into the inhaler from the protruding position into the retracted position, thereby bringing the container inside the inhaler; arranging delivery of the metered dose in the dose container to occur when the slide is stationary in the retracted position in the inhaler, whereby the dose container is accessed by dedicated, internal, opening elements, flow channels and aerosolizing elements of the inhaler.
17. The method of claim 16, characterized by the further step of optionally latching a breath-actuation mechanism of the inhaler to the opening of the dose container, such that a certain minimum suction pressure must be exceeded by an inhaling user before the dose container may be opened by internal opening elements of the inhaler and the dose accessed and released by an inhalation-induced airflow.
PCT/SE2005/000843 2004-06-07 2005-06-03 Securing dose quality of inhalable drug WO2005120616A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0401453A SE528190C2 (en) 2004-06-07 2004-06-07 Inhaler
SE0401453-6 2004-06-07
SE0401612-7 2004-06-18
SE0401612A SE530006C2 (en) 2004-06-18 2004-06-18 Inhaler using pods

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2005251670A AU2005251670B2 (en) 2004-06-07 2005-06-03 Securing dose quality of inhalable drug
EP20050748753 EP1765440A1 (en) 2004-06-07 2005-06-03 Securing dose quality of inhalable drug
JP2007527133A JP2008501473A (en) 2004-06-07 2005-06-03 Guarantee of dose quality of inhalable drug
CA 2569343 CA2569343A1 (en) 2004-06-07 2005-06-03 Securing dose quality of inhalable drug
RU2006145654/14A RU2006145654A (en) 2004-06-07 2005-06-03 Protecting the metered medicament for inhalation
BRPI0511891 BRPI0511891A (en) 2004-06-07 2005-06-03 process to ensure the quality of the dose of an inhalable drug
MXPA06014265A MXPA06014265A (en) 2004-06-07 2005-06-03 Securing dose quality of inhalable drug.
IL17948906A IL179489D0 (en) 2004-06-07 2006-11-22 Securing dose quality of inhalable drug
NO20070053A NO20070053L (en) 2004-06-07 2007-01-03 Securing dose quality inhalable medicine

Publications (1)

Publication Number Publication Date
WO2005120616A1 true WO2005120616A1 (en) 2005-12-22

Family

ID=35502846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/000843 WO2005120616A1 (en) 2004-06-07 2005-06-03 Securing dose quality of inhalable drug

Country Status (10)

Country Link
EP (1) EP1765440A1 (en)
JP (1) JP2008501473A (en)
AU (1) AU2005251670B2 (en)
BR (1) BRPI0511891A (en)
CA (1) CA2569343A1 (en)
IL (1) IL179489D0 (en)
MX (1) MXPA06014265A (en)
NO (1) NO20070053L (en)
RU (1) RU2006145654A (en)
WO (1) WO2005120616A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912193B2 (en) 2008-06-13 2014-12-16 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9393372B2 (en) 2008-06-13 2016-07-19 Mannkind Corporation Dry powder drug delivery system
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490797A1 (en) * 1990-12-13 1992-06-17 Tenax Corporation Inhalation actuated dispensing apparatus
US5415162A (en) * 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
US5595175A (en) * 1991-08-16 1997-01-21 Sandoz Ltd. Inhaler for administration of powdery substances
EP0759306A2 (en) * 1995-08-11 1997-02-26 Unisia Jecs Corporation Medicine administering apparatus
US6422236B1 (en) * 2000-09-25 2002-07-23 Microdrug Ag Continuous dry powder inhaler
US6698425B1 (en) * 1997-02-07 2004-03-02 Astrazeneca Ab Powder inhaler
US6722363B1 (en) * 1998-06-22 2004-04-20 Astrazeneca Ab Device for emptying cavities containing powder by means of suction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490797A1 (en) * 1990-12-13 1992-06-17 Tenax Corporation Inhalation actuated dispensing apparatus
US5595175A (en) * 1991-08-16 1997-01-21 Sandoz Ltd. Inhaler for administration of powdery substances
US5415162A (en) * 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
EP0759306A2 (en) * 1995-08-11 1997-02-26 Unisia Jecs Corporation Medicine administering apparatus
US6698425B1 (en) * 1997-02-07 2004-03-02 Astrazeneca Ab Powder inhaler
US6722363B1 (en) * 1998-06-22 2004-04-20 Astrazeneca Ab Device for emptying cavities containing powder by means of suction
US6422236B1 (en) * 2000-09-25 2002-07-23 Microdrug Ag Continuous dry powder inhaler

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9393372B2 (en) 2008-06-13 2016-07-19 Mannkind Corporation Dry powder drug delivery system
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8912193B2 (en) 2008-06-13 2014-12-16 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Also Published As

Publication number Publication date
RU2006145654A (en) 2008-07-20
IL179489D0 (en) 2007-05-15
AU2005251670B2 (en) 2010-04-22
EP1765440A1 (en) 2007-03-28
CA2569343A1 (en) 2005-12-22
AU2005251670A1 (en) 2005-12-22
JP2008501473A (en) 2008-01-24
MXPA06014265A (en) 2007-03-12
NO20070053L (en) 2007-01-03
BRPI0511891A (en) 2008-01-15

Similar Documents

Publication Publication Date Title
ES2252789T3 (en) Device for use with metered dose inhalers.
EP2377566B1 (en) Inhaler
ES2318890T3 (en) Metered dry powder medicaments provided with means of diverting the activated inhalation to cause distribution of the drug flow.
ES2250145T3 (en) Inhaler.
AU2002306007B2 (en) An inhalation device
EP1726324B1 (en) Medicament container with same side airflow inlet and outlet
EP1166812B1 (en) Packaging and delivery of pharmaceuticals and drugs
JP5564262B2 (en) Inhalation device for powdered medicament
US6880555B1 (en) Inhaler
US7658721B2 (en) Sublingual drug delivery device
ES2265157T3 (en) Inhaler for dry powder medicaments provided with means for the division of the flow driven by the inspiration to cause drug administration.
US5002048A (en) Inhalation device utilizing two or more aerosol containers
US5042472A (en) Powder inhaler device
US5161524A (en) Dosage inhalator with air flow velocity regulating means
US8205614B2 (en) Delivery device
AU684754B2 (en) Dry powder inhalator medicament carrier
JPH0620532Y2 (en) Device for administering a medicament to a patient
US5388572A (en) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US8047203B2 (en) Unit dose dry powder inhaler
US5533502A (en) Powder inhaler with aerosolization occurring within each individual powder receptacle
US8677992B2 (en) Simple capsule-based inhaler
US7987845B2 (en) Dry powder inhalers having spiral travel paths, unit dose microcartridges with dry powder, related devices and methods
US5301666A (en) Powder inhaler
AU680874B2 (en) Inhalation device
CN101400397B (en) Improvement of a dry powder inhaler

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 179489

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005251670

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 551570

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 7183/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2569343

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006502454

Country of ref document: PH

Ref document number: 200580018400.4

Country of ref document: CN

Ref document number: 2007527133

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014265

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005748753

Country of ref document: EP

Ref document number: 06130554

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2005251670

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2005251670

Country of ref document: AU

Date of ref document: 20050603

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200700132

Country of ref document: ZA

Ref document number: 2007/00132

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1200700025

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1020077000393

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006145654

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020077000393

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005748753

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0511891

Country of ref document: BR